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Background
Natural Killer (NK) cells are innate immunity lympho-
cytes that spontaneously recognise and kill melanoma
cells [1]. Dacarbazine synergises with host immunity by
inducing stress signals (NKG2D-L) that alert NK cells
[2]. This provides an example of how cancer therapies
and host innate immunity may be combined to improve
management of melanoma patients. BRAF inhibitors
(BRAFi) are radically changing clinical practice in mela-
noma treatment because they offer unprecedented survi-
val gains. However, melanoma patients nearly always
relapse with drug-resistant disease after 6-12 months
into the treatment. While evidence is emerging that
BRAFi may modulate host immunity, the effect of
BRAFi on the cross talk between NK cells and mela-
noma cells is unknown.
Material and methods
BRAF-mutant melanoma cell lines 1520, SK-MEL-37 and
Colo38 were cultured for 4 weeks in the presence of 5μM
vemurafenib. BRAFi-resistant variants were sequenced to
confirm the presence of the BRAFV600E mutation and
exclude outgrowth of BRAFWT clones. NK cells were iso-
lated from the blood of healthy donors and activated with
IL-2. Melanoma cell killing by NK cells was quantified
before and after BRAFi treatment by FACS (CD107 degra-
nulation assay) and/or by chromium release assays. MAPK
signalling in melanoma cells was quantified by FACS
(phospho-ERK). Expression of HLA class I, TRAIL, PD-1L
as well as ligands for NKG2D, NCRs and DNAM-1 on
melanoma cells was assessed by FACS. Receptor expres-
sion was assessed by FACS on blood NK cells from
healthy donors or by confocal microscopy in lymph node
biopsies of metastatic melanoma patients.
Results
Melanoma cells that acquired BRAFi resistance through
increased MAPK signalling developed also resistance
towards NK cell killing. Expression of HLA class I, PD-1L
and TRAIL was often elevated in drug-resistant melanoma
cells compared to parental melanoma cells, whereas the
expression of other NK receptor ligands did not signifi-
cantly change. PD-1 was found on a subset of NK cells
from some melanoma patients and on IL-2 activated NK
cells from some healthy donors.
Conclusion
These data suggest that the PD-1/PD-L1 pathway is an
attractive target to restore NK cell activity towards mela-
noma cells in some patients, thus harnessing host innate
immunity to combat acquired BRAFi-resistance.
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